Neuromuscular Day: Dr. Luis Querol

Keynote speaker: Professor Luis Querol, University of Barcelona

Topic: Autoimmune nodopathies: an emerging concept.

Dr Luis Querol Gutiérrez is the coordinator and principal investigator of the Autoimmune Neurology group at Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Dr Querol's research interests include autoimmune disease of the peripheral nervous system and translational research in the field of autoantibodies and immune-mediated neuropathies. His research has helped to define autoimmune nodopathies, clinically validate prognostic biomarkers in Guillain- Barré syndrome, and to monitor treatment response and disease burden in patients with inflammatory neuropathies. His research has contributed to the main consortia studying inflammatory neuropathies (IGOS, INCBase, iMAGine) and to the national consortium studying rare diseases (CIBERER). Dr Querol has received the Best Young Clinical Investigator CIBERNED 2013 award and the 2014 PK Thomas prize from the European Federation of Neurological Societies for his work with autoantibodies in chronic inflammatory demyelinating polyneuropathy.

Event Speakers:
Dr. Hans Katzberg, University of Toronto (UHN). MRI neurography in inflammatory neuropathies.
Dr. Juan Idiaquez, University of Toronto (UHN). Corneal dendritic cells: a potential neuroinflammation marker in small fibre neuropathy.
Dr. Vinaya Bhandari, University of Toronto (UHN). A simple single question to assess people with polyneuropathies.
Dr. Andrea Parks, University of Toronto (Sunnybrook). Exploring the experiences and perspectives of younger middle-aged adults with ALS and their family caregivers.
Dr. Carolina Barnett-Tapia, University of Toronto (UHN). Prednisone and risk of generalization in ocular Myasthenia gravis
Dr. Denizart Santos, University of Toronto (Sunnybrook). Neurophysiological Biomarkers in ALS.
Dr. Conrad Eng, University of Toronto. "Tongue in cheek: Macroglossia as a  rare presentation of a common neuromuscular condition?"
Dr. Rodrigo Martinez-Harms, University of Toronto (UHN). Time to achieve acceptable disease state in myasthenia gravis and outcomes in seronegative patients.
Dr. Dubravka Dodig, University of Toronto (UHN). Novel treatments for myasthenia gravis.

These rounds are generously supported through formal partnership with the Division of Neurology; Alexion, Amylyx, Biogen, EMD Serono, Grifols, Novartis, Paladin Labs, Roche, Sanofi Genzyme and Teva.